Therapie und Monitoring von Cushing-Patienten – Routine oder Herausforderung?

Der Hyperadrenokortizismus gehört zu den häufigen endokrinologischen Erkrankungen des älteren Hundes. Immer wieder gibt es Unklarheiten bezüglich Art der Therapie, Therapieeinstellung und Monitoring. Diesen Fragen soll hier gemäß dem aktuellen Stand der Wissenschaft nachgegangen werden.

• Literatur

• 1 Pérez-Alenza D, Melián C. Hyperadrenocorticism in Dogs. In: Ettinger SJ, Feldman EC, Côté E. Textbook of Veterinary Internal Medicine. St. Louis: Elsevier; 2017
• 2 Behrend EN. et al. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM Consensus Statement (Small Animal). J Vet Intern Med 2013; 27: 1292-1304
• 3 Nagata N, Kojima K, Yuki M. Comparison of survival times for dogs with pituitary-dependent hyperadrenocorticisim in a primary-care hospital: treated with trilostane versus untreated. J Vet Intern Med 2017; 31: 22-28
• 4 Behrend EN. Canine Hyperadrenocorticism. In: Feldman EC. et al., Hrsg. Canine & Feline Endocrinology. St. Louis: Elsevier; 2015
• 5 Ferguson DC, Peterson ME. Serum free and total iodothyronine concentrations in dogs with hyperadrenocorticism. Am J Vet Res 1992; 53 (09) 1636-1640
• 6 Kenefick SJ, Neiger R. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism. J Small Anim Pract 2008; 49 (03) 139-143
• 7 McLauchlan G. et al. Retrospective evaluation of the effect of trilostane on insulin requirement and fructosamine concentration in eight diabetic dogs with hyperadrenocorticism. J Small Anim Pract 2010; 52: 642-648
• 8 Park FM. et al. Hypercoagulability and ACTH-dependent hyperadrenocorticism in dogs. J Vet Intern Med 2013; 27: 1136-1142
• 9 Mawby DI, Whittemore JC, Fecteau KA. Canine pancreatic-specific lipase concentrations in clinically healthy dogs and dogs with naturally occurring hyperadrenocorticism. J Vet Intern Med 2014; 28: 1244-1250
• 10 Ramsey I. Monitoring treatment in canine hyperadrenocorticism. BSAVA Congress Proceedings. 2019
• 11 Barker EN. et al. A comparison of the survival times of dogs Treated with Mitotane or Trilostane for Pituitary-Dependent Hyperadrenocorticism. J Vet Intern Med 2005; 19: 810-815
• 12 Clemente M. et al. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2007; 161 (24) 805-809
• 13 Lemetayer J, Blois S. Update on the use of trilostane in dogs. Can Vet J 2018; 59: 397-407
• 14 Neiger R, Lehnert C. Treatment of canine hyperadrenocorticism (Cushingʼs disease) with trilostane. Tierärtzl Prax K H 2004; 32: 193-198
• 15 Feldman EC, Kass PH. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med 2012; 26: 1078-1080
• 16 Foster S. et al. Efficacy and safety of tightly controlled hyperadrenocorticism in dogs treated with trilostane in general practice. J Vet Intern Med 2020; 34: 3058-3166
• 17 Arenas Bermejo C. et al. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2020; 34: 1413-1422
• 18 Arenas C, Melián C, Pérez-Alenza MD. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily. J Vet Intern Med 2013; 27: 1478-1485
• 19 San José PG. et al. Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment. J Vet Intern Med 2021; 35: 130-141
• 20 King JB, Morton JM. Incidence and risk factors for hypoadrenocorticism in dogs treated with trilostane. Vet J 2017; 24-29
• 21 Bermejo CA. et al. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2020; 34: 1413-1422
• 22 Griebsch C. et al. Effect of trilostane on hormone and serum electrolyte concentrations in Dogs with Pituitary-Dependent Hyperadrenocorticism. J Vet Int Med 2014; 28: 160-165
• 23 Burkhardt WA. et al. Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats. Domest Anim Endocrinol 2011; 40: 155-164
• 24 Macfarlane L, Parkin T, Ramsey I. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. Vet Record 2016.
• 25 Midence JN, Drobatz KJ, Hess RS. Cortisol concentration in well-regulated dogs with hyperadrenocorticism treated with trilostane. J Vet Intern Med 2015; 29: 1529-1533
• 26 van Rijn SJ. et al. The influence of pituitary size on outcome after transphenoidal hypophysectomy in a large cohort of dogs with pituitary-dependent hypercortisolism. J Vet Intern Med 2016; 30: 989-995
• 27 Hanson JM. et al. Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005; 19: 687-694
• 28 Meij BP. Hypophysectomy as a treatment for canine and feline cushingʼs disease. Vet Clin North Am Small Anim Pract 2001; 31: 1015-1041
• 29 Arenas C, Melián C, Pérez-Alenza MD. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment. J Vet Intern Med 2014; 28: 473-480
• 30 Miceli DD, Pignataro OP, Castillo VA. Concurrent hyperadrenocorticism and diabetes mellitus in dogs. Res Vet Sci 2017; 115: 425-431